New Quinoline-Based Proteasome Inhibitors


Executive Summary


There are several existing cancer treatments that are effective at inducing cell death by decreasing proteasome activity: Velcade® (bortezomib) and Kyprolis® (carfilzomib). Due to undesirable side effects and pharmacodynamics properties, these agents have been limited to treating blood cancers.  MSU researchers have developed a new class of therapeutic compounds with a unique mode of action and more promising pharmacodynamics. 


Description of Technology


This technology uses a new class of quinoline-based proteasome inhibitors. These compounds differ from previous proteasome inhibitors by exhibiting uncompetitive reversible inhibition rather than competitive inhibition. This technology is effective against bortezomib-resistant Multiple Myeloma cells and has potential as a novel asthma treatment.


Key Benefits

  • Effective against drug-resistant myeloma cells
  • Has potential to target other cancers and diseases
  • Novel mechanism of inhibition
  • Simple chemical synthesis



  • Treating Multiple Myeloma
    • Inhibit proteasome function to kill cancer cell
    • Effective against bortezomib-resistant strains
  • Treating asthma
    • Same inhibition pathway


Patent Status: 


Under review


Licensing Rights Available


Full licensing rights available


Inventors: Aaron Odom, Jetze Tepe, Teri Lansdall


Tech ID: TEC2016-0123


Alternative contact due to temporary leave:


Nina (Isi) Davis, Technology Marketing Manager, email:, phone (direct): (517)884-1829. 


Patent Information:


For Information, Contact:

Anne Di Sante
Executive Director
Michigan State University